Articles

Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade

Articles, Business Consultant, Pharma Consultant

With no effective cure in Wet Age-related macular degeneration (Wet AMD) treatment market, the need of new therapies that can not only slow...

Read More

Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D

Articles, Business Consultant, Pharma Consultant

Nearly 11 million Americans are living with one or other type of Age-Related Macular degeneration (AMD), estimates BrightFocus foundation....

Read More

Good news for Kite’s KTE-X19, and Aquestive’s Libervant; and a commercialization deal between ReForm Biologics, MilliporeSigma

Articles, Business Consultant, Pharma Consultant

FDA has accepted Biological License Application submitted by Kite for its CAR-T cell therapy- KTE-X19, for relapsed or refractory mantle...

Read More

Bridging the gap: Nontuberculous mycobacterium Infections Drug Pipeline

Articles, Business Consultant, Pharma Consultant

Slowly or rapidly growing bacteria- Nontuberculous mycobacteria (NTM), might appear innocuous, however, NTM infections have a notably...

Read More

Nontuberculous Mycobacteria Infection Market: Current status of NTM infection drug discovery and development

Articles

Nontuberculous mycobacteria (NTM) are members of the Mycobacterium genus other than Mycobacterium tuberculosis complex and Mycobacterium...

Read More

Lack of effective therapy: A major Nontuberculous Mycobacteria Infection Market Driver

Articles, Business Consultant, Pharma Consultant

Nontuberculous Mycobacteria (NTM) is a ubiquitous, aerobic, non-motile, acid-fast bacteria, which, when inhaled, may cause severe lung...

Read More
Close